Evaluation of Procalcitonin and C-reactive Protein in Early Differential Diagnosis of Neonatal Jaundice

Liu, Qing; Dai, Xiaoyan; Lou, Shuang; Huang, Tingting; Chen, Junyao; Chen, Zhongbiao; Yu, Huijun; Lan, Xi; Cao, Zhaopeng; Zhou, Yiwen; Jia, Xingwang

doi:10.7754/clin.lab.2020.200330

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believe that the panels proposed by us in the present work have excellent predictive values compared with values reported for serological tests [(AUC (IgM): 0.81; AUC (IgG): 0.93; AUC (IgM + IgG): 0.98)] 39 ; and the RT-PCR test (AUC: 0.83) 40 . Studies aimed at evaluating the accuracy of laboratory parameters (neutrophil count, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase and urea) in predicting COVID-19 cases with positive RT-PCR for COVID-19 have demonstrated an AUC of just 0.8 41 .…”

Section: Discussionsupporting

confidence: 57%

Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19

López‐Hernández

Monárrez‐Espino

Oostdam

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Research exploring the development and outcome of COVID-19 infections has led to the need to find better diagnostic and prognostic biomarkers. This cross-sectional study used targeted metabolomics to identify potential COVID-19 biomarkers that predicted the course of the illness by assessing 110 endogenous plasma metabolites from individuals admitted to a local hospital for diagnosis/treatment. Patients were classified into four groups (≈ 40 each) according to standard polymerase chain reaction (PCR) COVID-19 testing and disease course: PCR−/controls (i.e., non-COVID controls), PCR+/not-hospitalized, PCR+/hospitalized, and PCR+/intubated. Blood samples were collected within 2 days of admission/PCR testing. Metabolite concentration data, demographic data and clinical data were used to propose biomarkers and develop optimal regression models for the diagnosis and prognosis of COVID-19. The area under the receiver operating characteristic curve (AUC; 95% CI) was used to assess each models’ predictive value. A panel that included the kynurenine: tryptophan ratio, lysoPC a C26:0, and pyruvic acid discriminated non-COVID controls from PCR+/not-hospitalized (AUC = 0.947; 95% CI 0.931–0.962). A second panel consisting of C10:2, butyric acid, and pyruvic acid distinguished PCR+/not-hospitalized from PCR+/hospitalized and PCR+/intubated (AUC = 0.975; 95% CI 0.968–0.983). Only lysoPC a C28:0 differentiated PCR+/hospitalized from PCR+/intubated patients (AUC = 0.770; 95% CI 0.736–0.803). If additional studies with targeted metabolomics confirm the diagnostic value of these plasma biomarkers, such panels could eventually be of clinical use in medical practice.

show abstract

Section: Discussionsupporting

confidence: 57%

Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19

López‐Hernández

Monárrez‐Espino

Oostdam

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Finally, it seems that CRP may allow for the prediction of early mortality in cirrhosis patients following esophageal variceal bleeding [ 345 , 346 , 347 , 348 ]. In addition, obstructive jaundice can be accompanied by elevated CRP levels, and it can also possess crucial clinical values in the differential diagnosis of neonatal jaundice [ 349 , 350 ]. Old data reveal that CRP has been notably increased in subjects with hepatic glycogen storage disease type 1 and in cases with secondary amyloidosis [ 351 , 352 ].…”

Section: Current Evidence On C-reactive Protein and Potential Conditionsmentioning

confidence: 99%

C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians

Mouliou

2023

Diseases

View full text Add to dashboard Cite

The current literature provides a body of evidence on C-Reactive Protein (CRP) and its potential role in inflammation. However, most pieces of evidence are sparse and controversial. This critical state-of-the-art monography provides all the crucial data on the potential biochemical properties of the protein, along with further evidence on its potential pathobiology, both for its pentameric and monomeric forms, including information for its ligands as well as the possible function of autoantibodies against the protein. Furthermore, the current evidence on its potential utility as a biomarker of various diseases is presented, of all cardiovascular, respiratory, hepatobiliary, gastrointestinal, pancreatic, renal, gynecological, andrological, dental, oral, otorhinolaryngological, ophthalmological, dermatological, musculoskeletal, neurological, mental, splenic, thyroid conditions, as well as infections, autoimmune-supposed conditions and neoplasms, including other possible factors that have been linked with elevated concentrations of that protein. Moreover, data on molecular diagnostics on CRP are discussed, and possible etiologies of false test results are highlighted. Additionally, this review evaluates all current pieces of evidence on CRP and systemic inflammation, and highlights future goals. Finally, a novel diagnostic algorithm to carefully assess the CRP level for a precise diagnosis of a medical condition is illustrated.

show abstract

High-density lipoprotein (HDL) has an impact on myeloma outcome: Lower HDL associates with worse progression-free survival

Özünal

Kılıçaslan

Elibol

et al. 2023

Wien Klin Wochenschr

View full text Add to dashboard Cite

Evaluation of Procalcitonin and C-reactive Protein in Early Differential Diagnosis of Neonatal Jaundice

Cited by 3 publications

References 0 publications

Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19

Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19

C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians

High-density lipoprotein (HDL) has an impact on myeloma outcome: Lower HDL associates with worse progression-free survival

Contact Info

Product

Resources

About